Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Researchers led by Karen Hvid of Copenhagen University Hospital, Herlev, are presenting at the EASD annual meeting in Milan an analysis of 313,145 adults with a BMI of 25 or higher and no coronary heart disease or diabetes, drawn from the Copenhagen General Population Study and UK Biobank and followed for up to 18 and 15 years. About 44% (Copenhagen) and 48% (UK Biobank) of people with a BMI of 25 to 26.9, who fall below current GLP-1 weight-loss eligibility, had elevated remnant cholesterol, low-grade inflammation, or both. Those with both markers and no drug indication were 41% (Copenhagen) and 47% (UK Biobank) more likely to develop heart disease than people without an indication and with healthy levels, compared with increases of 41% and 35% among people who already qualify for the drugs. The findings are observational, and the authors said clinical trials are needed.
Researchers at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and the University of Jena, with senior author Christian Hertweck, reported in Angewandte Chemie International Edition that Pandoraea bacteria, a group that includes opportunistic pathogens, make lipopeptide siderophores called pandorachelins. An enzyme called PdnM removes the fatty-acid tail from pandorachelin B, triggering a rearrangement that contracts its ring into pandorachelin A, a head-to-tail cyclic peptide. The tailed form works as a surfactant that helps the bacteria swarm, while the trimmed form binds iron more tightly but no longer promotes movement. The paper was published online on July 24, 2026 and described by phys.org on September 25; the authors suggested the findings could inform drug delivery, but no medical use has been tested.
UC San Diego researchers reported in the journal Molecular Therapy that catestatin, a naturally occurring fragment of the protein chromogranin A, reduced the buildup of amyloid and tau, lowered brain inflammation, and improved cognitive and motor function in mouse models of neurodegenerative disease, the university announced on September 22, 2026. The study was led by Suborno Jati, with senior author Sushil Mahata of UC San Diego and the VA San Diego Healthcare System. The university's announcement did not report numerical results. The authors called the findings preclinical and said catestatin's safety, dosing, and effectiveness must be established before it could be evaluated as a treatment in people.
An updated systematic review by Areesha Moiz, Mark Eisenberg, and colleagues, published online September 1, 2026 in the Annals of Internal Medicine, covered 38 randomized trials in 25,816 adults with overweight or obesity and without diabetes, adding 14 trials to the authors' earlier review. Among marketed drugs, the highest placebo-subtracted weight loss reported was 5.8% for liraglutide, 14.8% for subcutaneous semaglutide, 14.3% for oral semaglutide, 12.4% for orforglipron, and 19.0% for tirzepatide; emerging agents reached 23.9% with amycretin and 22.1% with retatrutide. Gastrointestinal adverse events occurred in 76.0% of patients on GLP-1 drugs versus 40.1% on placebo, and discontinuation for adverse events was 10.7% versus 3.4%. The authors said heterogeneity prevented a pooled quantitative analysis, so these figures are the highest values from individual trials rather than combined estimates.
Stanford researchers led by Eric Appel reported in the journal Matter, as described by phys.org on September 22, 2026, that they trained an AI model on known antimicrobial peptides and used it to screen 1.7 million candidate polyacrylamide polymers designed to mimic how those peptides kill bacteria. The team synthesized and tested 10 of the model's picks; all 10 performed well above expectations against E. coli, one was especially effective against biofilms, and the approach also worked against Staphylococcus aureus. Co-author Shoshana Williams called them among the most potent antimicrobial polymers ever reported. The polymers rip holes in bacterial membranes, a mechanism the researchers say makes resistance harder to evolve; clinical use remains a future goal.
Healthline reported on Friday, September 18, 2026 on a study by nference researchers, including Venky Soundararajan, published August 31 in Biology Methods & Protocols. The study followed 1,016 people who stayed on 2.5 mg tirzepatide for at least six months and 814 who took at least three 0.25 mg semaglutide doses over at least six months; at 12 months, weight loss averaged about 5.5% and 2.2%, respectively. At 24 months, people on sustained low-dose semaglutide had lower rates of constipation (23.3% vs 36.3%), nausea (39.7% vs 50.1%), and low blood pressure (1.7% vs 5.4%) than people on higher doses. Mir Ali, MD, of MemorialCare told Healthline that most patients will need some dose escalation to keep losing weight, and the article noted that dosing outside approved schedules is not FDA- or manufacturer-approved.
Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 6990) announced Monday September 14, 2026 that Phase 3 registrational study results for trastuzumab botidotin — a novel HER2-targeted antibody-drug conjugate — versus T-DM1 (Roche's Kadcyla, trastuzumab emtansine) in HER2-positive unresectable or metastatic breast cancer have been published in the Journal of Clinical Oncology. Trastuzumab botidotin produced 11.1 months median progression-free survival versus 4.4 months on T-DM1, a hazard ratio of 0.39 (61% reduction in risk of progression or death). Co-senior authors: Professors Xichun Hu and Hongxia Wang of Fudan University Shanghai Cancer Center, and Dr. Junyou Ge. The NMPA approved trastuzumab botidotin in October 2025 for adults with unresectable or metastatic HER2-positive breast cancer who had received at least one prior anti-HER2 therapy. The T-DM1 comparator (approved 2013) has historically been the standard of care in this second-line setting, though Daiichi Sankyo/AstraZeneca's Enhertu (trastuzumab deruxtecan) has since taken market share on stronger DESTINY-Breast trial data. Kelun-Biotech has opened a Phase 2 study of trastuzumab botidotin in patients who previously received a topoisomerase inhibitor payload ADC (which includes Enhertu-treated patients). The Phase 3 result strengthens the case for global development beyond China.
A systematic review and meta-analysis of head-to-head comparisons of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy) in adults with overweight or obesity — published in Diabetes, Obesity and Metabolism and covered by Medscape on September 9, 2026 with running weekend commentary — synthesized 10 studies (three randomized controlled trials and seven retrospective cohort studies) enrolling 41,381 adults. Tirzepatide produced a mean 4.28 percentage-point greater percent-body-weight reduction than semaglutide (10 studies) and a mean 4.43 kg greater absolute weight loss (8 studies). One head-to-head study reported average weight loss of 50.3 lbs (22.9 kg) on tirzepatide versus 33.1 lbs on semaglutide. Gastrointestinal adverse events were common in both arms but somewhat more frequent with tirzepatide; serious adverse event rates were rare but higher on tirzepatide than semaglutide. The pooled evidence supports the SURMOUNT-5 head-to-head randomized readout published in the New England Journal of Medicine in 2025 (Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks). The tirzepatide-semaglutide efficacy gap plus the safety trade-off remains a live clinical decision point in a market where 12%+ of U.S. adults are on the GLP-1 class per recent surveys.
A University of Pennsylvania School of Engineering and Applied Science team led by Neil K.R. Sehgal, Sharath Chandra Guntuku, Lyle Ungar, and Jena Shaw Tronieri published in Nature Health (Vol. 1, Issue 8, page 806; DOI 10.1038/s44360-026-00108-y) an AI-driven analysis of 410,198 Reddit posts from 67,008 users self-reporting use of semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) between May 2019 and June 2025. Gastrointestinal side effects dominated as expected (nausea 36.9%, fatigue 16.7%, vomiting 16.3%, constipation 15.3%, diarrhea 12.6%), and 43.5% of users reported at least one side effect. Two categories emerged as underreported in trials and worth investigation: reproductive symptoms including menstrual cycle changes and heavy bleeding (~4%), and thermoregulation symptoms (chills, hot flashes). The authors caution that Reddit users skew younger, male, and U.S.-based and note the analysis cannot establish causation. The hypothalamus regulates hunger, hormones, reproduction, and body temperature — a plausible biological substrate. Coverage syndicated Saturday September 12, 2026 (ScienceDaily and other outlets) after the Sept 13 journal publication date.
A study published September 4, 2026 in the American Academy of Pediatrics journal Pediatrics (DOI: 10.1542/peds.2026-077048) documented a 310-fold increase in GLP-1 receptor agonist prescribing in U.S. children aged 8 to 11 without diabetes and with obesity between 2019 and mid-2026 — from 0.03% of eligible children in 2019 to 9.3% in 2026. Prescribing captured liraglutide, semaglutide, and tirzepatide across the age group. Recipient characteristics: 93.7% had class II or III severe obesity at baseline, 65.2% had at least one weight-related comorbidity, and approximately 25% had prediabetes. Socioeconomic gradients were substantial: children in upper-income communities were prescribed GLP-1s at 55% higher rates than those in lower-income communities. The trend accelerated notably following the December 2022 FDA approval of Wegovy for adolescents 12 and older (implicit off-label use in the younger cohort) and shifted further after the AAP's January 2023 pediatric obesity clinical practice guideline. FoodNavigator syndicated the study September 10, 2026 alongside broad coverage this week; the data show how quickly clinical practice moved ahead of the STEP Young Phase 3 topline announced September 7.
Rein Therapeutics (NASDAQ: RNTX) presented Tuesday September 8, 2026 (poster PA6217, 12:30-2:00 p.m. CEST) at the European Respiratory Society Congress in Barcelona the Phase 1b randomized double-blind placebo-controlled dose-escalation study of inhaled LTI-03 in patients with idiopathic pulmonary fibrosis. LTI-03 is a first-in-class synthetic seven-amino-acid peptide derived from the caveolin-1 scaffolding domain (CSD), designed with a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. The trial randomized 24 IPF participants 3:1 to LTI-03 5 mg/day (N=9), LTI-03 10 mg/day (N=9), or placebo (N=6) for 14 days. LTI-03 was well-tolerated with no treatment-related discontinuations, no severe TEAEs, and no spirometry-based airway obstruction; both doses significantly reduced interleukin-11 (p=0.0406 at 5 mg/day; p=0.044 at 10 mg/day) and thymic stromal lymphopoietin. The results were published the same day in Nature Communications (Philip Molyneaux MD, Imperial College London, presenting). LTI-03 has FDA Orphan Drug and Fast Track designations (Fast Track granted August 2026); the Phase 2 RENEW trial is enrolling across five countries with interim data anticipated H2 2026.
Trevi Therapeutics (NASDAQ: TRVI) confirmed via its September 3, 2026 conference-participation announcement that Marlies Wijsenbeek MD PhD (Erasmus MC) will deliver an oral presentation on quality-of-life outcomes measured by the Leicester Cough Questionnaire (LCQ) from the Phase 2b CORAL trial of nalbuphine extended-release (Haduvio, an oral kappa-opioid agonist / mu-opioid antagonist) in idiopathic pulmonary fibrosis patients with chronic cough at the European Respiratory Society Congress in Barcelona. The 165-patient Phase 2b CORAL topline (reported June 2025) documented statistically significant reductions in 24-hour objective cough frequency across all Haduvio dose groups at week 6, with reductions seen at week 2 (the first time point measured). Trevi has completed the End-of-Phase 2 FDA meeting and continued Phase 3 initiation preparation through 2026. Chronic cough affects approximately 85% of IPF patients and has no FDA-approved treatment; the Merck-Bellus P2X3 antagonist gefapixant (Lyfnua) was approved for refractory chronic cough in adults in 2024 but was not developed for IPF-specific cough.
Transgene (Euronext Paris: TNG) and NEC Corporation announced Wednesday September 2, 2026 sustained 100% three-year disease-free survival with TG4050 (a personalized neoantigen vaccine using Transgene's myvac vectorized viral platform combined with NEC's AI-driven neoantigen selection) in the Phase 1 portion of a randomized Phase 1/2 trial evaluating adjuvant treatment for HPV-negative head and neck squamous cell carcinoma following surgery and chemoradiotherapy. Strong and persistent CD8+ T-cell responses against patient-specific tumor neoantigens were observed and maintained for more than one year after the last vaccination. The Phase 1 clinical and translational findings were published in Nature Communications. Next milestones: first immunological data from the Phase 2 portion expected H2 2026, and two-year efficacy data (DFS) from Phase 2 expected Q1 2028. The result extends the personalized neoantigen vaccine class case established by the Merck-Moderna intismeran (mRNA-4157) August 19 Phase 3 INTerpath-001 melanoma win, and continues to build the peptide-based cancer vaccine category outside the mRNA modality.
Nature Chemical Biology published in August 2026 a research paper describing computational design of antimicrobial peptide nanopores that self-assemble into pore structures selective for bacterial membranes. The lead candidate compound, designated KDFA2i + 9-NH2, was administered intraperitoneally in a mouse infection model and reduced bacterial load by approximately 2 logs — a magnitude comparable to the reference antibiotic levofloxacin at equivalent doses. The nanopore mechanism differs from the standard cationic amphipathic peptide (CAP) mechanism of most antimicrobial peptides in that KDFA2i-class molecules assemble on the bacterial membrane into discrete transmembrane pores rather than disrupting the membrane through nonspecific electrostatic interactions. The design approach uses molecular dynamics simulations combined with generative chemistry to search sequence space for compounds that both self-assemble into a specific pore geometry and select for bacterial versus mammalian membranes. The result adds to the July 2026 Nature Communications publication of the generative-AI-designed antimicrobial peptide Arcinin (which killed drug-resistant bacteria in a mouse wound model while sparing human cells), continuing the computational-design-first shift in the antimicrobial peptide field.
Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.
Cytokinetics (NASDAQ: CYTK) confirmed Monday August 31, 2026 the peer-reviewed publication of ACACIA-HCM additional analyses in Circulation and MAPLE-HCM in Journal of the American College of Cardiology: Heart Failure, both following the ESC Congress 2026 Late-Breaking Clinical Trial Session presentations Saturday August 29 in Munich. The ACACIA-HCM Circulation paper details cardiac structure and diastolic function improvements from aficamten (Myqorzo) in symptomatic non-obstructive hypertrophic cardiomyopathy (LV mass reduction, LV wall thickness reduction, and LA volume reduction versus placebo at Week 36), supporting the ACACIA-HCM primary readout (KCCQ Clinical Summary Score and peak VO2) that was presented Friday August 28 in the Hot Line Session and published simultaneously in the New England Journal of Medicine. The MAPLE-HCM JACC: Heart Failure paper reports the trial of aficamten versus metoprolol in obstructive HCM. Cytokinetics plans an aficamten sNDA submission in Q4 2026 for the non-obstructive HCM indication.
Wiley's Diabetes, Obesity and Metabolism published in August 2026 pooled subgroup analyses from Novo Nordisk's Phase 3 SOUL (oral semaglutide 14 mg in type 2 diabetes with ASCVD/CKD) and SELECT (semaglutide 2.4 mg in overweight/obesity with established cardiovascular disease) trials examining whether cardiovascular benefit of semaglutide varies by baseline aspirin use. Analyses (Müller-Wieland et al.) concluded that semaglutide significantly reduces major adverse cardiovascular events irrespective of baseline aspirin therapy in individuals with T2DM or overweight/obesity without diabetes at high cardiovascular risk. The pooled MACE benefit is directionally consistent in aspirin users and non-users. Clinical implication: cardiovascular protection from semaglutide is additive to baseline antiplatelet therapy and does not require aspirin discontinuation, addressing a long-standing question about interaction between the GLP-1 receptor agonist class and standard secondary-prevention regimens in older cardiovascular patients.
Nature published in late August 2026 a research paper (Membranolytic peptide programs immunogenic cell death for cancer therapy, DOI 10.1038/s41586-026-10899-5) characterizing aMPC16-CA50, a pH-responsive membranolytic peptide that induces immunogenic membranolytic cell death (ICD) in tumor cells and, when combined with immune checkpoint blockade therapy (PD-1/PD-L1 inhibitors), strongly potentiates antitumor immune response in preclinical tumor models. The peptide is engineered for selective activity in the acidic microenvironment of solid tumors, sparing normal tissue at physiological pH, and its cell-death mechanism releases damage-associated molecular patterns (DAMPs) that prime dendritic cell antigen presentation and cross-priming of tumor-antigen-specific CD8+ T cells. The work adds a new mechanism to the growing membranolytic peptide anti-cancer literature that includes host-defense-peptide-derived candidates (LL-37, defensins), venom-derived amphipathic peptides (melittin analogs), and synthetic amphiphile designs. Clinical translation remains preclinical.